Jung-Sik Kim

TL;DR: The data presented here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours.

TL;DR: Studying a near-diploid human cell line with a stable karyotype, it is found that targeted inactivation of STAG2 led to chromatid cohesion defects and aneuploidy, whereas in two aneuPLoid human glioblastoma cell lines, targeted correction of the endogenous mutant alleles of STAE led to enhanced chromosomal stability.

TL;DR: The largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines) is reported, finding that EFT has a very low mutational burden but frequent deleterious mutations in the cohesin complex subunit STAG2 and that 11% of tumors pathologically diagnosed as EFT lack a typical EWSR1 fusion oncogene and these tumors do not have a characteristic Ewing sarcoma gene expression signature.

TL;DR: The results support clinical trial evaluation of PD-0332991 against newly diagnosed as well as recurrent GBM, and indicate that Rb status is the primary determinant of potential benefit from this therapy.

TL;DR: Akt may be a central player in a feedback loop whereby activation of Akt induced by IR increases radioresistance of GBM cells, and targeting the Akt signaling pathway may have important therapeutic implications when used in combination with IR.